AU2022357544A1 - Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta - Google Patents

Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta Download PDF

Info

Publication number
AU2022357544A1
AU2022357544A1 AU2022357544A AU2022357544A AU2022357544A1 AU 2022357544 A1 AU2022357544 A1 AU 2022357544A1 AU 2022357544 A AU2022357544 A AU 2022357544A AU 2022357544 A AU2022357544 A AU 2022357544A AU 2022357544 A1 AU2022357544 A1 AU 2022357544A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
antibody
sclerostin antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022357544A
Other languages
English (en)
Inventor
Emil Kakkis
Alastair MACKINNON
Arun MISTRY
Michael S. OMINSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mereo Biopharma 3 Ltd
Ultragenyx Pharmaceutical Inc
Original Assignee
Mereo Biopharma 3 Ltd
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 3 Ltd, Ultragenyx Pharmaceutical Inc filed Critical Mereo Biopharma 3 Ltd
Publication of AU2022357544A1 publication Critical patent/AU2022357544A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2022357544A 2021-09-30 2022-09-29 Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta Pending AU2022357544A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163250918P 2021-09-30 2021-09-30
US63/250,918 2021-09-30
US202263374982P 2022-09-08 2022-09-08
US63/374,982 2022-09-08
PCT/US2022/077259 WO2023056355A2 (en) 2021-09-30 2022-09-29 Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta

Publications (1)

Publication Number Publication Date
AU2022357544A1 true AU2022357544A1 (en) 2024-04-11

Family

ID=85783647

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022357544A Pending AU2022357544A1 (en) 2021-09-30 2022-09-29 Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta

Country Status (9)

Country Link
US (1) US20250011407A1 (https=)
EP (1) EP4408884A4 (https=)
JP (1) JP2024536106A (https=)
KR (1) KR20240082380A (https=)
AU (1) AU2022357544A1 (https=)
CA (1) CA3233220A1 (https=)
MX (1) MX2024003828A (https=)
TW (1) TW202323278A (https=)
WO (1) WO2023056355A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025212547A1 (en) * 2024-04-05 2025-10-09 Amgen Inc. Methods of treating osteogenesis imperfecta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517672A (ja) * 2008-03-24 2011-06-16 アボツト・バイオテクノロジー・リミテツド 骨損失を治療するための方法及び組成物
MA41142A (fr) * 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
KR20190037261A (ko) * 2016-08-08 2019-04-05 암젠 인크 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
MX2019007161A (es) * 2016-12-21 2020-02-12 Mereo Biopharma 3 Ltd Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
US10961305B2 (en) * 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
GB201810746D0 (en) * 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist

Also Published As

Publication number Publication date
JP2024536106A (ja) 2024-10-04
EP4408884A2 (en) 2024-08-07
TW202323278A (zh) 2023-06-16
CA3233220A1 (en) 2023-04-06
MX2024003828A (es) 2024-05-10
US20250011407A1 (en) 2025-01-09
WO2023056355A2 (en) 2023-04-06
EP4408884A4 (en) 2025-04-23
KR20240082380A (ko) 2024-06-10
WO2023056355A3 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
US12582712B2 (en) Method of making anti-pro/latent myostatin antibodies
US11925683B2 (en) Compositions for making and using anti-Myostatin antibodies
JP6353500B2 (ja) Ｄｋｋ１抗体およびその使用方法
US20250011407A1 (en) Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta
AU2023203922B2 (en) Anti-pro/latent-Myostatin antibodies and uses thereof
HK40117719A (en) Anti-pro/latent-myostatin antibodies and uses thereof